{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Will be summarized using descriptive statistics.","groups":[{"description":"The Outcome Measure was assessed in aggregate, combining participants from both phases of the study, as per the planned protocol.\n\nPhase 1, Dose 1 received entospletinib at Dose Level 1: 400 mg daily (200 mg twice daily) in combination with obinutuzumab during Dose Escalation phase of study.\n\nPhase 1, Dose 2 received entospletinib at Dose Level 2: 800 mg daily (400 mg twice daily) in combination with obinutuzumab during Dose Escalation phase of study.\n\nPhase 2, MTD: Received entospletinib at Maximum Tolerated Dose (MTD) in combination with obinutuzumab during Dose Expansion phase of study. The MTD was determined to be 800 mg daily (400 mg twice daily).","id":"OG000","title":"All Research Participants"}],"populationDescription":"Data for this outcome was not collected due to PI transition.","reportingStatus":"POSTED","timeFrame":"Up to 45 months","title":"Peripheral Blood B-cell Depletion and Recovery","type":"OTHER_PRE_SPECIFIED"}